Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Metrics to compare | ANVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANVSPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −2.0x | −0.5x | |
PEG Ratio | −0.03 | −0.08 | 0.00 | |
Price/Book | 2.2x | 0.8x | 2.6x | |
Price / LTM Sales | - | 90.8x | 3.2x | |
Upside (Analyst Target) | - | 197.2% | 41.9% | |
Fair Value Upside | Unlock | 18.6% | 4.3% | Unlock |